skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma

Review

(2132) Views  (615) Full article downloads

Authors: Peter E Clark

Published Date June 2010 Volume 2010:4 Pages 187 - 197
DOI: http://dx.doi.org/10.2147/BTT.S7818

Peter E Clark

Vanderbilt University Medical Center, Nashville, Tennessee, USA

Abstract: Advanced renal cell carcinoma (RCC) remains a challenging, major health problem. Recent advances in understanding the fundamental biology underlying one form of RCC, ie, clear cell (or conventional) RCC, have opened the door to a series of targeted agents, such as the tyrosine kinase inhibitors (TKIs), which have become the standard of care in managing advanced clear cell RCC. Among the newest of these agents to receive Food and Drug Administration approval in this disease is pazopanib. This review will summarize what is known about the fundamental biology that underlies clear cell RCC, the data surrounding the previously approved targeted agents for this disease, including not only the TKIs but also the mTOR inhibitors and the vascular endothelial growth factor-specific agent, bevacizumab, and the newest TKI, pazopanib. It will also explore the potential role for pazopanib relative to the other available agents and where it may fit into the armamentarium for treatment of advanced/metastatic RCC.

Keywords: pazopanib, targeted therapy, tyrosine kinase inhibitor, clear cell renal cell carcinoma








Readers of this article also read:

α-L-iduronidase therapy for mucopolysaccharidosis type I
Therapeutic vaccines for malignant brain tumors
Safety of etanercept in elderly subjects with rheumatoid arthritis
Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model
Hepatitis B virus and Homo sapiens proteomewide analysis: A profusion of viral peptide overlaps in neuron-specific human proteins
Palliative treatment of malignant ascites: profile of catumaxomab
Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention
Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed